Combination Targeted Treatment Produces Lasting Remissions in People With Resistant Aggressive B-Cell Lymphoma June 19, 2024 — Researchers have developed a non-chemotherapy treatment regimen ...

Finding God has been the answer for Olivia Anderson, 46, a Norfolkan who has been fighting an ongoing battle with lymphoma ...

Although usually identified early, skin lymphomas can be mistaken for other skin conditions, delaying diagnosis. Non-Hodgkin's lymphoma (NHL) occurs when lymphocytes called T cells and B cells become ...

What Is B-Cell Lymphoma? B-cell lymphoma is a cancer that forms in your white blood cells called lymphocytes. These cells are made by your lymphatic system, which plays an important role in immunity.

A test for abnormal fetal chromosomes can also detect maternal cancers—and physicians are struggling to incorporate that ...

Learn what to expect when you see a rheumatologist for the first time, with expert recommendations on how to get the most out ...

An example of how CD-20 can be used to tell cells apart is given here: There are two very different cancers that look like identical twins under the microscope, but have very different disease courses ...

At the second attempt, the FDA has approved Citius Pharmaceuticals' marketing application for Lymphir, a new version of a lymphoma therapy withdrawn from sale several years ago. The US regulator ...

Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications ...

Lymphoma is a type of cancer that begins in immune system cells, called lymphocytes. It generally presents as a solid tumor of lymphoid cells and can develop in the lymph nodes, spleen, bone ...

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.

The stent hadn’t helped after all; the impacted kidney had, in fact, been irreversibly damaged and was now functioning at a ...